Although STAT3 degraders and inhibitors all target STAT3 to exert their anticancer activities, it was unclear whether the presence and abundance of STAT3 protein in cancer cells correlate with or predict cell sensitivities or responses to these STAT3‐targeting agents. The gene discussed is STAT3; the disease is cancer.